Tulathromycin A
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
泰拉霉素A(Tulathromycin A)是大环内酯类抗生素[1].抗生素是一种用于治疗和预防细菌感染的抗菌剂.
将两只高致病菌株牛分枝杆菌孵育进145只小牛中.4天后,在患有临床牛呼吸道疾病(BRD)的小牛皮下注射泰拉霉素或生理盐水(2.5 mg/kg).在泰拉霉素用药的小牛体内, 牛呼吸道疾病相关的戒断\直肠温度峰值及肺病变记分显著降低[2].在治疗有可能发展成牛呼吸道疾病的高风险牛时,泰拉霉素(78%)和替米考星(tilmicosin )(65%) 的治愈率明显高于生理盐水(23.8%).泰拉霉素(78.4%)的治愈率也明显高于替米考星(64.9%) [3].
泰拉霉素抑制90%的溶血性曼氏杆菌(巴斯德氏菌) (MIC90)生长的最低浓度为2 μg/ml,对多杀性巴氏杆菌(牛)的最低浓度为1 μg/ml,对多杀性巴氏杆菌(猪)的最低浓度为2 μg/ml,对睡眠嗜组织菌的最低浓度为0.5-4 μg/ml,对胸膜肺炎放线杆菌的最低浓度为4-16 μg/ml[1].已批准泰拉霉素可用于治疗和预防猪与牛的呼吸道疾病[1].
参考文献：
[1]. Godinho KS, et al. Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology.Vet Ther, 2005, 6(2): 113-121.
[2]. Godinho KS, et al. Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves.Vet Ther, 2005, 6(2): 96-112.
[3]. Kilgore WR, Spensley MS, Sun F, et al. Therapeutic efficacy of tulathromycin, a novel triamilide antimicrobial, against bovine respiratory disease in feeder calves.Vet Ther, 2005, 6(2): 143-153.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 806.08 |
| Cas No. | 217500-96-4 |
| Formula | C41H79N3O12 |
| Synonyms | Tulathromycin;Draxxin;CP 472295 |
| Solubility | ≥24.1 mg/mL in DMSO; insoluble in H2O; ≥96.8 mg/mL in EtOH |
| Chemical Name | 11-((4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-3,4,10-trihydroxy-13-((5-hydroxy-4-methoxy-4,6-dimethyl-5-((propylamino)methyl)tetrahydro-2H-pyran-2-yl)oxy)-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one |
| SDF | Download SDF |
| Canonical SMILES | CCCNCC1(O)C(C)OC(OC2C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(C)(O)CC(C)CNC(C)C(O)C(C)(O)C(CC)OC(C2C)=O)CC1(OC)C |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| 细胞实验 [1]： | |
|
细胞系 |
大肠杆菌， 溶血性曼氏杆菌，多杀巴斯德氏菌 |
|
溶解方法 |
在DMSO中的溶解度≥24.1 mg/mL 的。为了获得更高的浓度，可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
|
反应条件 |
0.5μg/ml～16μg/ml |
|
应用 |
Tulathromycin A是一种大环内酯类抗生素，通过作用50S核糖体亚基进而抑制细菌蛋白质合成（IC50 = 0.26 µM），阻止新生多肽链的形成。 |
| 动物实验 [2]： | |
|
动物模型 |
牛和猪 |
|
剂量 |
2.5 mg/kg（i.m.） |
|
应用 |
在牛和猪中，tulathromycin的特点是皮下（s.c.）和肌肉（i.m.）给药吸收率快，全身可用率高。 相反，使用复方制剂口服tulathromycin，全身可用率较低（～50％）。在血浆中，tulathromycin具有较长的终末半衰期，除了小鼠终末半衰期小于20小时之外，其范围为～2到～5天。在驹中（～140小时）可以看到血浆中最长的终末半衰期。 |
|
注意事项 |
请测试所有化合物在室内的溶解度，实际溶解度和理论值可能略有不同，这是由实验系统的误差引起的，属于正常现象。 |
|
References: [1]. Andersen NM, Poehlsgaard J, Warrass R, Douthwaite S. Inhibition of protein synthesis on the ribosome by tildipirosin compared with other veterinary macrolides. Antimicrob Agents Chemother. 2012 Nov;56(11):6033-6. doi: 10.1128/AAC.01250-12. Epub 2012 Aug 27. PMID: 22926570; PMCID: PMC3486562. [2]. Villarino N, Brown SA, Martín-Jiménez T. Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective. J Vet Pharmacol Ther. 2014 Jun;37(3):211-21. doi: 10.1111/jvp.12080. Epub 2013 Sep 30. PMID: 24117832. |
|
